南非阿斯利康制药周一表示，将向恩诺根医疗国际出售其女性健康产品Ovestin的欧洲商业化权利及相关知识产权，交易金额为1.97亿欧元（约2.2亿美元）。
记者 Nqobile Dludla 报道 阿斯利康称，专注于欧洲市场的恩诺根还将收购价值约400万欧元的相关库存。
作为交易的一部分，阿斯利康与恩诺根签署了长期供应协议，阿斯利康将继续在欧洲生产和供应Ovestin的活性药物成分和乳膏制剂，期限至少为10年。
该协议是阿斯利康战略的一部分，旨在从核心关注点——新兴市场之外的资产中释放价值。
South Africa's Aspen Pharmacare will sell the European commercialisation rights and related intellectual property for its women's health product Ovestin to Ennogen Healthcare International for €197 million ($220 million), it said on Monday.
阿斯利康还将向恩诺根提供为期五年的战略支持服务，月费为100万欧元，并提供长达三年的过渡服务，以促进业务移交。
在阿斯利康2026财年，Ovestin产生了约7.56亿兰特（约4500万美元）的收入和2.38亿兰特的税后利润。
公司表示，交易所得将根据其资本配置战略处理，股票回购仍是其向股东回报资本的首选方式。
By Nqobile Dludla Europe-focused Ennogen will also buy related inventory valued at about €4 million, Aspen said As part of the deal, Aspen and Ennogen have long-term supply agreements under which Aspen will continue manufacturing and supplying the active pharmaceutical ingredient and cream formulation of Ovestin in Europe for at least 10 years The agreement forms part of Aspen's strategy to unlock value from assets outside its core focus on emerging markets Aspen will also provide strategic support services to Ennogen for five years for a fee of €1 million per month, and transitional services for up to three years to facilitate the transfer of the business Ovestin generated revenue of about 756 million rand ($45 million) and profit after tax of 238 million rand in Aspen's 2026 financial year The company said proceeds from the transaction would be subject to its capital allocation strategy, with share buybacks remaining its preferred method of returning capital to shareholders